The typical metabolic modifiers conferring improvement in cancer resistance

Current Medicinal Chemistry

Volumn 24, Issue 34, 2017, Pages 3698-3710

  Tan, Wen ^a   Zhong, Zhangfeng ^b   Wang, Shengpeng ^b   Liu, Hui ^a   Yu, Hua ^b   Tan, Rui ^c   Hu, Xiaodong ^a   Pan, Tingrui ^d   Wang, Yitao ^b  

^a LANZHOU UNIVERSITY   (China)

^b University of Macau   (Macao)

^c SOUTHWEST JIAOTONG UNIVERSITY   (China)

^d University of California Davis   (United States)

Author keywords

2 deoxy Dglucose; 3 bromopyruvate; Cancer metabolic reprogramming; Cancer resistance; Lonidamine; Metabolic modifiers

Indexed keywords

3 BROMOPYRUVATE; ANTINEOPLASTIC AGENT; DEOXYGLUCOSE; LONIDAMINE; PYRUVIC ACID DERIVATIVE; UNCLASSIFIED DRUG; BROMOPYRUVATE; FATTY ACID; INDAZOLE DERIVATIVE;

CANCER RESISTANCE; CANCER THERAPY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; METABOLIC REGULATION; NONHUMAN; REVIEW; BIOSYNTHESIS; CHEMISTRY; DRUG DESIGN; DRUG EFFECTS; DRUG RESISTANCE; METABOLIC ENGINEERING; METABOLISM; NEOPLASM; OXIDATIVE PHOSPHORYLATION; PATHOLOGY;

ANTINEOPLASTIC AGENTS; DRUG DESIGN; DRUG RESISTANCE, NEOPLASM; FATTY ACIDS; HUMANS; INDAZOLES; METABOLIC ENGINEERING; NEOPLASMS; OXIDATIVE PHOSPHORYLATION; PYRUVATES;

EID: 85038222811     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/0929867324666170203121449     Document Type: Review

References (121)

1. Pelicano, H.; Martin, D.S.; Xu, R.H.; Huang, P. Glycolysis inhibition for anticancer treatment. Oncogene, 2006, 25(34), 4633-4646.
2. Law, A.A.; Collie-Duguid, E.S.; Smith, T.A. Influence of resistance to 5-fluorouracil and tomudex on [18F]FDG incorporation, glucose transport and hexokinase activity. Int. J. Oncol., 2012, 41(1), 378-382.
3. Tozzi, F.; Zhou, Y.; Chen, J.; Bose, D.; Fan, F.; Xia, L.; Wang, J.; Brusher, H.; Widger, W.; Ellis, L.M.; Waihua, Z. Abstract 4075: Chemoresistant colorectal cancer cells exhibit high glycolytic activity. Cancer Res., 2011, 71(8 Supplement), 4075.
4. Olszewski, U.; Zeillinger, R.; Geissler, K.; Hamilton, G. Genome-wide gene expression analysis of chemoresistant pulmonary carcinoid cells. Lung Cancer, 2010, 1, 107-117.
5. Pribluda, A.; de la Cruz, C.C.; Jackson, E.L. Intratumoral Heterogeneity: From Diversity Comes Resistance. Clin. Cancer Res., 2015, 21(13), 2916-2923.
6. Wintzell, M.; Lofstedt, L.; Johansson, J.; Pedersen, A.B.; Fuxe, J.; Shoshan, M. Repeated cisplatin treatment can lead to a multiresistant tumor cell population with stem cell features and sensitivity to 3-bromopyruvate. Cancer boil. therap., 2012, 13(14), 1454-1462.
7. Long, Y.; Tsai, W.B.; Wangpaichitr, M.; Tsukamoto, T.; Savaraj, N.; Feun, L.G.; Kuo, M.T. Arginine deiminase resistance in melanoma cells is associated with metabolic reprogramming, glucose dependence, and glutamine addiction. Mol. Cancer Ther., 2013, 12(11), 2581-2590.
8. DeNicola, G.M.; Cantley, L.C., Cancer's fuel choice: New flavors for a picky eater. Mol. Cell, 2015, 60(4), 514-523.
9. Xu, R.H.; Pelicano, H.; Zhou, Y.; Carew, J.S.; Feng, L.; Bhalla, K.N.; Keating, M.J.; Huang, P. Inhibition of glycolysis in cancer cells: A novel strategy to overcome drug resistance associated with mitochondrial respiratory defect and hypoxia. Cancer Res., 2005, 65(2), 613-621.
10. Bhatt, A.N.; Chauhan, A.; Khanna, S.; Rai, Y.; Singh, S.; Soni, R.; Kalra, N.; Dwarakanath, B.S. Transient elevation of glycolysis confers radio-resistance by facilitating DNA repair in cells. BMC Cancer, 2015, 15, 335.
11. Fukuda, S.; Miyata, H.; Miyazaki, Y.; Makino, T.; Takahashi, T.; Kurokawa, Y.; Yamasaki, M.; Nakajima, K.; Takiguchi, S.; Mori, M.; Doki, Y. Pyruvate kinase M2 modulates esophageal squamous cell carcinoma chemotherapy response by regulating the pentose phosphate pathway. Ann. Surg. Oncol., 2015. Suppl 3, S1461-S1468
12. Suh, D.H.; Kim, M.A.; Kim, H.; Kim, M.K.; Kim, H.S.; Chung, H.H.; Kim, Y.B.; Song, Y.S. Association of overexpression of hexokinase II with chemoresistance in epithelial ovarian cancer. J. Clin. Exp. Med., 2014, 14(3), 345-353.
13. Ledoux, S.; Yang, R.; Friedlander, G.; Laouari, D. Glucose depletion enhances P-glycoprotein expression in hepatoma cells: role of endoplasmic reticulum stress response. Cancer Res., 2003, 63(21), 7284-7290.
14. Song, K.; Li, M.; Xu, X.J.; Xuan, L.; Huang, G.N.; Song, X.L.; Liu, Q.F. HIF-1alpha and GLUT1 gene expression is associated with chemoresistance of acute myeloid leukemia. Asian Pac. J. Cancer Prev., 2014, 15(4), 1823-1829.
15. Min, J.W.; Kim, K.I.; Kim, H.A.; Kim, E.K.; Noh, W.C.; Jeon, H.B.; Cho, D.H.; Oh, J.S.; Park, I.C.; Hwang, S.G.; Kim, J.S. INPP4B-mediated tumor resistance is associated with modulation of glucose metabolism via hexokinase 2 regulation in laryngeal cancer cells. Biochem. Biophys. Res. Commun., 2013, 440(1), 137-142.
16. Suh, D.H.; Kim, H.S.; Kim, B.; Song, Y.S. Metabolic orchestration between cancer cells and tumor microenvironment as a co-evolutionary source of chemoresistance in ovarian cancer: a therapeutic implication. Biochem. Pharmacol., 2014, 92(1), 43-54.
17. Pina, Y.; Decatur, C.; Murray, T.G.; Houston, S.K.; Lopez- Cavalcante, M.; Hernandez, E.; Celdran, M.; Shah, N.; Feuer, W.; Lampidis, T. Retinoblastoma treatment: utilization of the glycolytic inhibitor, 2-deoxy-2-fluoro-D-glucose (2-FG), to target the chemoresistant hypoxic regions in LH(BETA)T(AG) retinal tumors. Invest. Ophthalmol. Vis. Sci., 2012, 53(2), 996-1002.
18. Furtado, C.M.; Marcondes, M.C.; Sola-Penna, M.; de Souza, M.L.; Zancan, P. Clotrimazole preferentially inhibits human breast cancer cell proliferation, viability and glycolysis. PLoS One, 2012, 7(2), e30462.
19. Coelho, R.G.; Calaca Ide, C.; Celestrini Dde, M.; Correia, A.H.; Costa, M.A.; Sola-Penna, M. Clotrimazole disrupts glycolysis in human breast cancer without affecting nontumoral tissues. Mol. Genet. Metab., 2011, 103(4), 394-398.
20. Marcondes, M.C.; Sola-Penna, M.; Zancan, P. Clotrimazole potentiates the inhibitory effects of ATP on the key glycolytic enzyme 6-phosphofructo-1-kinase. Arch .Biochem Biophys., 2010, 497(1-2), 62-67.
21. Klarer, A.C.; O'Neal, J.; Imbert-Fernandez, Y.; Clem, A.; Ellis, S.R.; Clark, J.; Clem, B.; Chesney, J.; Telang, S. Inhibition of 6-phosphofructo-2-kinase (PFKFB3) induces autophagy as a survival mechanism. Cancer Metab., 2014, 2(1), 2.
22. Marin-Hernandez, A.; Gallardo-Perez, J.C.; Lopez- Ramirez, S.Y.; Garcia-Garcia, J.D.; Rodriguez-Zavala, J.S.; Ruiz-Ramirez, L.; Gracia-Mora, I.; Zentella-Dehesa, A.; Sosa-Garrocho, M.; Macias-Silva, M.; Moreno-Sanchez, R.; Rodriguez-Enriquez, S. Casiopeina II-gly and bromo pyruvate inhibition of tumor hexokinase, glycolysis, and oxidative phosphorylation. Arch. Toxicol., 2012, 86(5), 753-766.
23. Lu, Q.Y.; Zhang, L.; Yee, J.K.; Go, V.W.; Lee, W.N. Metabolic consequences of LDHA inhibition by epigallocatechin gallate and oxamate in MIA PaCa-2 pancreatic cancer Cells. Metabolomics, 2015, 11(1), 71-80.
24. Dalva-Aydemir, S.; Bajpai, R.; Martinez, M.; Adekola, K.U.; Kandela, I.; Wei, C.; Singhal, S.; Koblinski, J.E.; Raje, N.S.; Rosen, S.T.; Shanmugam, M. Targeting the metabolic plasticity of multiple myeloma with FDAapproved ritonavir and metformin. Clin. Cancer Res., 2015, 21(5), 1161-1171.
25. Adekola, K.U.; Dalva Aydemir, S.; Ma, S.; Zhou, Z.; Rosen, S.T.; Shanmugam, M. Investigating and targeting chronic lymphocytic leukemia metabolism with the human immunodeficiency virus protease inhibitor ritonavir and metformin. Leuk. Lymphoma, 2015, 56(2), 450-459.
26. Lin, J.A.; Wu, C.H.; Lu, C.C.; Hsia, S.M.; Yen, G.C. Glycative stress from advanced glycation end products (AGEs) and dicarbonyls: An emerging biological factor in cancer onset and progression. Mol. Nutr. Food Res., 2016, 60(8), 1850-1864
27. Nass, N.; Sel, S.; Ignatov, A.; Roessner, A.; Kalinski, T. Oxidative stress and glyoxalase I activity mediate dicarbonyl toxicity in MCF-7 mamma carcinoma cells and a tamoxifen resistant derivative. Biochim. Biophys. Acta., 2016, 1860(6), 1272-1280.
28. Thornalley, P.J.; Rabbani, N. Glyoxalase in tumourigenesis and multidrug resistance. Semin. Cell Dev. Biol., 2011, 22(3), 318-325.
29. Wei, L.; Dai, Q.; Zhou, Y.; Zou, M.; Li, Z.; Lu, N.; Guo, Q. Oroxylin A sensitizes non-small cell lung cancer cells to anoikis via glucose-deprivation-like mechanisms: c-Src and hexokinase II. Biochim. Biophys. Acta, 2013, 1830(6), 3835-3845.
30. Ravagnan, L.; Marzo, I.; Costantini, P.; Susin, S.A.; Zamzami, N.; Petit, P.X.; Hirsch, F.; Goulbern, M.; Poupon, M.F.; Miccoli, L.; Xie, Z.; Reed, J.C.; Kroemer, G. Lonidamine triggers apoptosis via a direct, Bcl-2-inhibited effect on the mitochondrial permeability transition pore. Oncogene, 1999, 18(16), 2537-2546.
31. Floridi, A.; Gentile, F.P.; Bruno, T.; Delpino, A.; Iacobini, C.; Paggi, M.G.; Castiglione, S.; Benassi, M. Thermal behavior of a human glioma cell line and its response to combinations of hyperthermia and lonidamine. Oncol. Res., 1993, 5(1), 1-10.
32. Band, P.R.; Maroun, J.; Pritchard, K.; Stewart, D.; Coppin, C.M.; Wilson, K.; Eisenhauer, E.A. Phase II study of lonidamine in patients with metastatic breast cancer: A National Cancer Institute of Canada Clinical Trials Group Study. Cancer Treat Rep., 1986, 70(11), 1305-1310.
33. Ben-Horin, H.; Tassini, M.; Vivi, A.; Navon, G.; Kaplan, O. Mechanism of action of the antineoplastic drug lonidamine: 31P and 13C nuclear magnetic resonance studies. Cancer Res., 1995, 55(13), 2814-2821.
34. Vivi, A.; Tassini, M.; Ben-Horin, H.; Navon, G.; Kaplan, O. Comparison of action of the anti-neoplastic drug lonidamine on drug-sensitive and drug-resistant human breast cancer cells: 31P and 13C nuclear magnetic resonance studies. Breast Cancer Res. Treat, 1997, 43(1), 15-25.
35. Del Bufalo, D.; Biroccio, A.; Soddu, S.; Laudonio, N.; D'Angelo, C.; Sacchi, A.; Zupi, G. Lonidamine induces apoptosis in drug-resistant cells independently of the p53 gene. J. Clin. Invest., 1996, 98(5), 1165-1173.
36. Biroccio, A.; Del Bufalo, D.; Fanciulli, M.; Bruno, T.; Zupi, G.; Floridi, A. bcl-2 inhibits mitochondrial metabolism and lonidamine-induced apoptosis in adriamycin-resistant MCF7 cells. Int. J. Cancer, 1999, 82(1), 125-130.
37. Villa, R.; Zaffaroni, N.; Orlandi, L.; Bearzatto, A.; Costa, A.; Silvestrini, R. In vitro effect of lonidamine on the cytotoxicity of mitomycin C and BCNU in human colon adenocarcinoma cells. Eur. J. cancer, 1994, 30A(10), 1534-1540.
38. Silvestrini, R.; Gornati, D.; Zaffaroni, N.; Bearzatto, A.; De Marco, C. Modulation by lonidamine on the combined activity of cisplatin and epidoxorubicin in human breast cancer cells. Breast cancer res., 1997, 42(2), 103-112.
39. Bhutia, Y.D.; Babu, E.; Ganapathy, V. Re-programming tumour cell metabolism to treat cancer: No lone target for lonidamine. Biochem J., 2016, 473(11), 1503-1506.
40. Nath, K.; Nelson, D.S.; Heitjan, D.F.; Leeper, D.B.; Zhou, R.; Glickson, J.D. Lonidamine induces intracellular tumor acidification and ATP depletion in breast, prostate and ovarian cancer xenografts and potentiates response to doxorubicin. NMR Biomed., 2015, 28(3), 281-290.
41. Assanhou, A.G.; Li, W.; Zhang, L.; Xue, L.; Kong, L.; Sun, H.; Mo, R.; Zhang, C. Reversal of multidrug resistance by co-delivery of paclitaxel and lonidamine using a TPGS and hyaluronic acid dual-functionalized liposome for cancer treatment. Biomaterials, 2015, 73, 284-295.
42. Milane, L.; Duan, Z.; Amiji, M. Therapeutic efficacy and safety of paclitaxel/lonidamine loaded EGFR-targeted nanoparticles for the treatment of multi-drug resistant cancer. PLoS One, 2011, 6(9), e24075.
43. Li, N.; Zhang, C.X.; Wang, X.X.; Zhang, L.; Ma, X.; Zhou, J.; Ju, R.J.; Li, X.Y.; Zhao, W.Y.; Lu, W.L. Development of targeting lonidamine liposomes that circumvent drugresistant cancer by acting on mitochondrial signaling pathways. Biomaterials, 2013, 34(13), 3366-3380.
44. Cervantes-Madrid, D.; Romero, Y.; Duenas-Gonzalez, A. Reviving lonidamine and 6-Diazo-5-oxo-L-norleucine to be used in combination for metabolic cancer Therapy. Biomed Res. Int., 2015, 2015, 690492.
45. Zhang, B.F.; Xing, L.; Qiao, J.B.; Cui, P.F.; Wang, F.Z.; Zhang, J.L.; Xu, C.X.; Jiang, H.L. In vivo synergistic antitumor effect and safety of siRNA and lonidamine dualloaded hierarchical targeted nanoparticles. Int. J. Pharm., 2016, 506(1-2), 207-213.
46. Ning, S.C.; Hahn, G.M. Cytotoxicity of lonidamine alone and in combination with other drugs against murine RIF-1 and human HT1080 cells in vitro. Cancer Res., 1990, 50 (24), 7867-7870.
47. Citro, G.; Cucco, C.; Verdina, A.; Zupi, G. Reversal of adriamycin resistance by lonidamine in a human breast cancer cell line. Br. J. Cancer, 1991, 64(3), 534-536.
48. Floridi, A.; Gambacurta, A.; Bagnato, A.; Bianchi, C.; Paggi, M.G.; Silvestrini, B.; Caputo, A. Modulation of adriamycin uptake by lonidamine in Ehrlich ascites tumor cells. Exp. Mol. Pathol., 1988, 49(3), 421-431.
49. Floridi, A.; Bruno, T.; Miccadei, S.; Fanciulli, M.; Federico, A.; Paggi, M.G. Enhancement of doxorubicin content by the antitumor drug lonidamine in resistant Ehrlich ascites tumor cells through modulation of energy metabolism. Biochemical. Pharmacol., 1998, 56(7), 841-849.
50. Popert, R.J.; Masters, J.R.; Coptcoat, M.; Zupi, G. Relative cytotoxicities of adriamycin and epirubicin in combination with lonidamine against human bladder cancer cell lines. Urol. Res., 1995, 22(6), 367-372.
51. Fanciulli, M.; Valentini, A.; Bruno, T.; Citro, G.; Zupi, G.; Floridi, A. Effect of the antitumor drug lonidamine on glucose metabolism of adriamycin-sensitive and -resistant human breast cancer cells. Oncol. Res., 1996, 8(3), 111-120.
52. Silvestrini, R.; Zaffaroni, N.; Villa, R.; Orlandi, L.; Costa, A. Enhancement of cisplatin activity by lonidamine in human ovarian cancer cells. Int. J. Cancer, 1992, 52(5), 813-817.
53. Kiura, K.; Ohnoshi, T.; Ueoka, H.; Takigawa, N.; Tabata, M.; Segawa, Y.; Shibayama, T.; Kimura, I. An adriamycinresistant subline is more sensitive than the parent human small cell lung cancer cell line to lonidamine. Anticancer Drug Des., 1992, 7(6), 463-470.
54. Dell'Antone, P.; Bragadin, M.; Piergallini, L. Lonidamine cytotoxicity: Involvement of the lysosomal compartment. J Int Med Res, 2000, 28(6), 269-276.
55. Pratesi, G.; De Cesare, M.; Zunino, F. Efficacy of lonidamine combined with different DNA-damaging agents in the treatment of the MX-1 tumor xenograft. Cancer Chemother. Pharmacol., 1996, 38(2), 123-128.
56. Price, G.S.; Page, R.L.; Riviere, J.E.; Cline, J.M.; Thrall, D.E. Pharmacokinetics and toxicity of oral and intravenous lonidamine in dogs. Cancer Chemother. Pharmacol., 1996, 38(2), 129-135.
57. Tomirotti, M.; Bernardo, G.; Epifani, C.; Biasioli, R.; Franchi, R.; Mensi, F.; Carnaghi, P.; Schieppati, G.; Scanni, A. Recovery of response to adriamycin and cyclophosphamide by lonidamine in previously treated metastatic breast-cancer patients. Int. J. oncol., 1993, 3(2), 213-217.
58. Amadori, D.; Frassineti, G.L.; De Matteis, A.; Mustacchi, G.; Santoro, A.; Cariello, S.; Ferrari, M.; Nascimben, O.; Nanni, O.; Lombardi, A.; Scarpi, E.; Zoli, W. Modulating effect of lonidamine on response to doxorubicin in metastatic breast cancer patients: results from a multicenter prospective randomized trial. Breast cancer res., 1998, 49(3), 209-217.
59. Dogliotti, L.; Berruti, A.; Buniva, T.; Zola, P.; Bau, M.G.; Farris, A.; Sarobba, M.G.; Bottini, A.; Alquati, P.; Deltetto, F.; Gosso, P.; Monzeglio, C.; Moro, G.; Sussio, M.; Perroni, D. Lonidamine significantly increases the activity of epirubicin in patients with advanced breast cancer: results from a multicenter prospective randomized trial. J. Clin. Oncol., 1996, 14(4), 1165-1172.
60. Ianniello, G.P.; De Cataldis, G.; Comella, P.; Scarpati, M.D.; Maiorino, A.; Brancaccio, L.; Cioffi, R.; Lombardi, A.; Carnicelli, P.; Tinessa, V. Cisplatin, epirubicin, and vindesine with or without lonidamine in the treatment of inoperable nonsmall cell lung carcinoma: A multicenter randomized clinical trial. Cancer, 1996, 78(1), 63-69.
61. Lopez, M.; Carpano, S.; Dilauro, L.; Chiatti, L.; Vici, P.; Cavaliere, F.; Gentile, P.; Citro, G. Clinical modulation of epirubicin resistance by lonidamine in patients with advanced soft-tissue sarcomas. Int. J. oncol., 1995, 6(2), 363-367.
62. Iaffaioli, R.V.; Tortoriello, A.; Facchini, G.; Santangelo, M.; Bucci, L.; Fei, L.; Di Martino, N.; Mantovani, G.; Caponigro, F. Phase II study of high-dose epirubicin, lonidamine, alpha 2b interferon in advanced breast cancer. Breast Cancer Res., 1995, 35(3), 243-248.
63. Lopez, M.; Vici, P.; Di Lauro, L.; Paoletti, G.; Gionfra, T.; Conti, F.; Carpano, S.; Pignatti, F.; Giannarelli, D. Intrapatient comparison of single-agent epirubicin with or without lonidamine in metastatic breast cancer. Eur. J. Cancer, 1995, 31A(10), 1611-1614.
64. Papaldo, P.; Lopez, M.; Cortesi, E.; Cammilluzzi, E.; Antimi, M.; Terzoli, E.; Lepidini, G.; Vici, P.; Barone, C.; Ferretti, G.; Di Cosimo, S.; Nistico, C.; Carlini, P.; Conti, F.; Di Lauro, L.; Botti, C.; Vitucci, C.; Fabi, A.; Giannarelli, D.; Marolla, P. Addition of either lonidamine or granulocyte colony-stimulating factor does not improve survival in early breast cancer patients treated with high-dose epirubicin and cyclophosphamide. J. Clin. Oncol., 2003, 21(18), 3462-3468.
65. Gridelli, C.; De Marinis, F.; Rossi, A.; Tucci, E.; D'Aprile, M.; Cioffi, R.; Cortesi, E.; Migliorino, R.; Pisano, A.; Scognamiglio, F.; Di Giacomo, R.; Bianco, A.R. A phase II study of VM-26 plus lonidamine in pretreated small cell lung cancer. Anticancer Res., 1997, 17(2B), 1277-1279.
66. Dogliotti, L.; Danese, S.; Berruti, A.; Zola, P.; Buniva, T.; Bottini, A.; Richiardi, G.; Moro, G.; Farris, A.; Bau, M.G.; Porcile, G. Cisplatin, epirubicin, and lonidamine combination regimen as first-line chemotherapy for metastatic breast cancer: a pilot study. Cancer chemother. pharmacol., 1998, 41(4), 333-338.
67. Sordet, O.; Rebe, C.; Leroy, I.; Bruey, J.M.; Garrido, C.; Miguet, C.; Lizard, G.; Plenchette, S.; Corcos, L.; Solary, E. Mitochondria-targeting drugs arsenic trioxide and lonidamine bypass the resistance of TPA-differentiated leukemic cells to apoptosis. Blood, 2001, 97(12), 3931-3940.
68. Villa, R.; Orlandi, L.; Berruti, A.; Dogliotti, L.; Zaffaroni, N., Modulation of cytotoxic drug activity by mitotane and lonidamine in human adrenocortical carcinoma cells. Int. J. oncol., 1999, 14(1), 133-138.
69. Saurabh, S.; Sanjay, P.; Anant, N.B.; Richa, C.; Vikas, B.; Namita, K.; Ravi, S.; Bal, G.R.; Daman, S.; Bilikere, S.D. Chronic dietary administration of the glycolytic inhibitor 2- Deoxy-D-Glucose (2- DG) inhibits the growth of implanted ehrlich's ascites tumor in mice. PLoS One, 2015, e0132089.
70. Ranftler, C.; Meisslitzer-Ruppitsch, C.; Stangl, H.; Rohrl, C.; Fruhwurth, S.; Neumuller, J.; Pavelka, M.; Ellinger, A. 2-Deoxy-D-glucose treatment changes the Golgi apparatus architecture without blocking synthesis of complex lipids. Histochem. Cell Biol., 2015, 143(4), 369-380.
71. Kavaliauskiene, S.; Skotland, T.; Sylvanne, T.; Simolin, H.; Klokk, T.I.; Torgersen, M.L.; Lingelem, A.B.; Simm, R.; Ekroos, K.; Sandvig, K. Novel actions of 2-deoxy-Dglucose: Protection against Shiga toxins and changes in cellular lipids. Biochem. J., 2015, 470(1), 23-37.
72. Zhang, X.D.; Deslandes, E.; Villedieu, M.; Poulain, L.; Duval, M.; Gauduchon, P.; Schwartz, L.; Icard, P. Effect of 2-deoxy-D-glucose on various malignant cell lines in vitro. Anticancer Res, 2006, 26(5A), 3561-3566.
73. Kern, K.A.; Norton, J.A. Inhibition of established rat fibrosarcoma growth by the glucose antagonist 2-deoxy-Dglucose. Surgery, 1987, 102(2), 380-385.
74. Wang, Z.; Zhang, L.; Zhang, D.; Sun, R.; Wang, Q.; Liu, X. Glycolysis inhibitor 2-deoxy-D-glucose suppresses carcinogen- induced rat hepatocarcinogenesis by restricting cancer cell metabolism. Mol. Med. Rep., 2015, 11(3), 1917- 1924.
75. Zhang, D.; Li, J.; Wang, F.; Hu, J.; Wang, S.; Sun, Y. 2- Deoxy-D-glucose targeting of glucose metabolism in cancer cells as a potential therapy. Cancer Lett., 2014, 355(2), 176-183.
76. Ahadova, A.; Gebert, J.; von Knebel Doeberitz, M.; Kopitz, J.; Kloor, M. Dose-dependent effect of 2-deoxy-D-glucose on glycoprotein mannosylation in cancer cells. IUBMB Life, 2015, 67(3), 218-226.
77. Larrue, C.; Saland, E.; Vergez, F.; Serhan, N.; Delabesse, E.; Mansat-De Mas, V.; Hospital, M.A.; Tamburini, J.; Manenti, S.; Sarry, J.E.; Recher, C. Antileukemic activity of 2- Deoxy-d-Glucose through inhibition of N-linked glycosylation in acute myeloid leukemia with FLT3-ITD or c-KIT mutations. Mol. Cancer Ther., 2015, 14(10), 2364-2373.
78. Jain, V.K.; Kalia, V.K.; Sharma, R.; Maharajan, V.; Menon, M. Effects of 2-deoxy-D-glucose on glycolysis, proliferation kinetics and radiation response of human cancer cells. Int. J. Radiat. Oncol. Biol. Phys., 1985, 11(5), 943-950.
79. DeSalvo, J.; Kuznetsov, J.N.; Du, J.; Leclerc, G.M.; Leclerc, G.J.; Lampidis, T.J.; Barredo, J.C. Inhibition of Akt potentiates 2-DG-induced apoptosis via downregulation of UPR in acute lymphoblastic leukemia. Mol. Cancer Res., 2012, 10(7), 969-978.
80. Xi, H.; Kurtoglu, M.; Liu, H.; Wangpaichitr, M.; You, M.; Liu, X.; Savaraj, N.; Lampidis, T.J. 2-Deoxy-D-glucose activates autophagy via endoplasmic reticulum stress rather than ATP depletion. Cancer Chemother. Pharmacol., 2011, 67(4), 899-910.
81. Bentley, J.; Bell, S.E.; Quinn, D.M.; Kellett, G.L.; Warr, J.R. 2-deoxy-D-glucose toxicity and transport in human multidrug-resistant KB carcinoma cell lines. Oncol. Res., 1996, 8(2), 77-84.
82. Bell, S.E.; Quinn, D.M.; Kellett, G.L.; Warr, J.R. 2-Deoxy- D-glucose preferentially kills multidrug-resistant human KB carcinoma cell lines by apoptosis. Brit. J. cancer, 1998, 78(11), 1464-1470.
83. Aft, R.L.; Zhang, F.W.; Gius, D. Evaluation of 2-deoxy-Dglucose as a chemotherapeutic agent: Mechanism of cell death. Brit. J. Cancer, 2002, 87(7), 805-812.
84. Nelson, C.A.; Wang, J.Q.; Leav, I.; Crane, P.D. The interaction among glucose transport, hexokinase, and glucose-6- phosphatase with respect to 3H-2-deoxyglucose retention in murine tumor models. Nucl. Med. Biol., 1996, 23(4), 533-541.
85. Maher, J.C.; Wangpaichitr, M.; Savaraj, N.; Kurtoglu, M.; Lampidis, T.J. Hypoxia-inducible factor-1 confers resistance to the glycolytic inhibitor 2-deoxy-D-glucose. Mol. Cancer Ther., 2007, 6(2), 732-741.
86. Goldberg, L.; Israeli, R.; Kloog, Y. FTS and 2-DG induce pancreatic cancer cell death and tumor shrinkage in mice. Cell Death Dis., 2012, 3, e284.
87. Hunter, A.J.; Blekkenhorst, G.H. The effects of 2- deoxyglucose and amino-oxyacetic acid on the radiation response of mammalian cells in vitro. Int. J. Radiat. Biol., 1998, 73(3), 311-324.
88. Maher, J.C.; Krishan, A.; Lampidis, T.J. Greater cell cycle inhibition and cytotoxicity induced by 2-deoxy-D-glucose in tumor cells treated under hypoxic vs aerobic conditions. Cancer chemother. Pharmacol., 2004, 53(2), 116-122.
89. Sullivan, E.J.; Kurtoglu, M.; Brenneman, R.; Liu, H.; Lampidis, T.J. Targeting cisplatin-resistant human tumor cells with metabolic inhibitors. Cancer chemother. Pharmacol., 2014, 73(2), 417-427.
90. Purohit, S.C.; Pohlit, W. Experimental evaluation of the glucose antimetabolite, 2-deoxy-D-glucose (2-DG) as a possible adjuvant to radiotherapy of tumors: I. Kinetics of growth and survival of Ehrlich ascites tumor cells (EATC) in vitro and of growth of solid tumors after 2-DG and Xirradiation. Int. J. Radiat. Oncol. Biol. Phys., 1982, 8(3-4), 495-499.
91. Aghaee, F.; Pirayesh Islamian, J.; Baradaran, B. Enhanced radiosensitivity and chemosensitivity of breast cancer cells by 2-deoxy-d-glucose in combination therapy. J. breast cancer, 2012, 15(2), 141-147.
92. Khaitan, D.; Chandna, S.; Dwarakanath, S.B. Short-term exposure of multicellular tumor spheroids of a human glioma cell line to the glycolytic inhibitor 2-deoxy-Dglucose is more toxic than continuous exposure. J. Cancer Res. Ther., 2009, 5 Suppl 1, S67-S73.
93. Singh, D.; Banerji, A.K.; Dwarakanath, B.S.; Tripathi, R.P.; Gupta, J.P.; Mathew, T.L.; Ravindranath, T.; Jain, V. Optimizing cancer radiotherapy with 2-deoxy-d-glucose dose escalation studies in patients with glioblastoma multiforme. Strahlenther. Oncol., 2005, 181(8), 507-514.
94. Mohanti, B.K.; Rath, G.K.; Anantha, N.; Kannan, V.; Das, B.S.; Chandramouli, B.A.; Banerjee, A.K.; Das, S.; Jena, A.; Ravichandran, R.; Sahi, U.P.; Kumar, R.; Kapoor, N.; Kalia, V.K.; Dwarakanath, B.S.; Jain, V. Improving cancer radiotherapy with 2-deoxy-D-glucose: phase I/II clinical trials on human cerebral gliomas. Int. J. Radiat. Oncol. Biol. Phys., 1996, 35(1), 103-111.
95. Nelson, K. 3-Bromopyruvate kills cancer cells in animals. Lancet Oncol., 2002, 3(9), 524.
96. Geschwind, J.F.; Ko, Y.H.; Torbenson, M.S.; Magee, C.; Pedersen, P.L. Novel therapy for liver cancer: direct intraarterial injection of a potent inhibitor of ATP production. Cancer Res., 2002, 62(14), 3909-3913.
97. Vali, M.; Liapi, E.; Kowalski, J.; Hong, K.; Khwaja, A.; Torbenson, M.S.; Georgiades, C.; Geschwind, J.F. Intraarterial therapy with a new potent inhibitor of tumor metabolism (3-bromopyruvate): Identification of therapeutic dose and method of injection in an animal model of liver cancer. J. Vasc. Interv. Radiol., 2007, 18(1 Pt 1), 95-101.
98. Vossen, J.A.; Buijs, M.; Syed, L.; Kutiyanwala, F.; Kutiyanwala, M.; Geschwind, J.F.; Vali, M., Development of a new orthotopic animal model of metastatic liver cancer in the rabbit VX2 model: Effect on metastases after partial hepatectomy, intra-arterial treatment with 3-bromopyruvate and chemoembolization. Clin Exp Metastasis, 2008, 25(7), 811-817.
99. Macchioni, L.; Davidescu, M.; Sciaccaluga, M.; Marchetti, C.; Migliorati, G.; Coaccioli, S.; Roberti, R.; Corazzi, L.; Castigli, E. Mitochondrial dysfunction and effect of antiglycolytic bromopyruvic acid in GL15 glioblastoma cells. J. Bioenerg. Biomembr., 2011, 43(5), 507-518.
100. Davidescu, M.; Macchioni, L.; Scaramozzino, G.; Cristina Marchetti, M.; Migliorati, G.; Vitale, R.; Corcelli, A.; Roberti, R.; Castigli, E.; Corazzi, L. The energy blockers bromopyruvate and lonidamine lead GL15 glioblastoma cells to death by different p53-dependent routes. Sci. Rep., 2015, 5, 14343.
101. Zhang, X.; Varin, E.; Briand, M.; Allouche, S.; Heutte, N.; Schwartz, L.; Poulain, L.; Icard, P. Novel therapy for malignant pleural mesothelioma based on anti-energetic effect: an experimental study using 3-Bromopyruvate on nude mice. Anticancer Res., 2009, 29(4), 1443-1448.
102. Buijs, M.; Vossen, J.A.; Geschwind, J.F.; Ishimori, T.; Engles, J.M.; Acha-Ngwodo, O.; Wahl, R.L.; Vali, M. Specificity of the anti-glycolytic activity of 3- bromopyruvate confirmed by FDG uptake in a rat model of breast cancer. Invest. New Drugs, 2009, 27(2), 120-123.
103. Filomeni, G.; Cardaci, S.; Da Costa Ferreira, A.M.; Rotilio, G.; Ciriolo, M.R. Metabolic oxidative stress elicited by the copper(II) complex [Cu(isaepy)2] triggers apoptosis in SHSY5Y cells through the induction of the AMP-activated protein kinase/p38MAPK/p53 signalling axis: Evidence for a combined use with 3-bromopyruvate in neuroblastoma treatment. Biochem. J., 2011, 437(3), 443-453.
104. Kim, J.S.; Ahn, K.J.; Kim, J.A.; Kim, H.M.; Lee, J.D.; Lee, J.M.; Kim, S.J.; Park, J.H. Role of reactive oxygen speciesmediated mitochondrial dysregulation in 3-bromopyruvate induced cell death in hepatoma cells : ROS-mediated cell death by 3-BrPA. J. Bioenerg. Biomembr., 2008, 40(6), 607-618.
105. Sanchez-Arago, M.; Cuezva, J.M. The bioenergetic signature of isogenic colon cancer cells predicts the cell death response to treatment with 3-bromopyruvate, iodoacetate or 5-fluorouracil. J. Transl. Med., 2011, 9, 19.
106. Nakano, A.; Miki, H.; Nakamura, S.; Harada, T.; Oda, A.; Amou, H.; Fujii, S.; Kagawa, K.; Takeuchi, K.; Ozaki, S.; Matsumoto, T.; Abe, M. Up-regulation of hexokinaseII in myeloma cells: Targeting myeloma cells with 3- bromopyruvate. J. Bioenerg. Biomembr., 2012, 44(1), 31-38.
107. Xiao, H.; Li, S.; Zhang, D.; Liu, T.; Yu, M.; Wang, F. Separate and concurrent use of 2-deoxy-D-glucose and 3-bromopyruvate in pancreatic cancer cells. Oncol. Rep., 2013, 29(1), 329-334.
108. Xian, S.L.; Cao, W.; Zhang, X.D.; Lu, Y.F. Inhibitory effects of 3-bromopyruvate on human gastric cancer implant tumors in nude mice. Asian Pac. J. Cancer Prev., 2014, 15(7), 3175-3178.
109. El Sayed, S.M.; Mohamed, W.G.; Seddik, M.A.; Ahmed, A.S.; Mahmoud, A.G.; Amer, W.H.; Helmy Nabo, M.M.; Hamed, A.R.; Ahmed, N.S.; Abd-Allah, A.A. Safety and outcome of treatment of metastatic melanoma using 3- bromopyruvate: a concise literature review and case study. Chin. J. Cancer, 2014, 33(7), 356-364.
110. Gandham, S.K.; Talekar, M.; Singh, A.; Amiji, M.M. Inhibition of hexokinase-2 with targeted liposomal 3- bromopyruvate in an ovarian tumor spheroid model of aerobic glycolysis. Int. J. Nanomedicine, 2015, 10, 4405-4423.
111. Nilsson, H.; Lindgren, D.; Mandahl Forsberg, A.; Mulder, H.; Axelson, H.; Johansson, M.E. Primary clear cell renal carcinoma cells display minimal mitochondrial respiratory capacity resulting in pronounced sensitivity to glycolytic inhibition by 3-Bromopyruvate. Cell Death Dis., 2015, 6, e1585.
112. Ganapathy-Kanniappan, S.; Vali, M.; Kunjithapatham, R.; Buijs, M.; Syed, L.H.; Rao, P.P.; Ota, S.; Kwak, B.K.; Loffroy, R.; Geschwind, J.F. 3-bromopyruvate: a new targeted antiglycolytic agent and a promise for cancer therapy. Curr. Pharm. Biotechnol., 2010, 11(5), 510-517.
113. Cardaci, S.; Desideri, E.; Ciriolo, M.R. Targeting aerobic glycolysis: 3-bromopyruvate as a promising anticancer drug. J. Bioenerg. Biomembr., 2012, 44(1), 17-29.
114. Ganapathy-Kanniappan, S.; Kunjithapatham, R.; Geschwind, J.F. Anticancer efficacy of the metabolic blocker 3- bromopyruvate: specific molecular targeting. Anticancer Res., 2013, 33(1), 13-20.
115. Galina, A. Mitochondria: 3-bromopyruvate vs. mitochondria? A small molecule that attacks tumors by targeting their bioenergetic diversity. Int. J. Biochem. Cell Biol., 2014, 54, 266-271.
116. Azevedo-Silva, J.; Queiros, O.; Ribeiro, A.; Baltazar, F.; Young, K.H.; Pedersen, P.L.; Preto, A.; Casal, M. The cytotoxicity of 3-bromopyruvate in breast cancer cells depends on extracellular pH. Biochem. J., 2015, 467(2), 247-258.
117. Macchioni, L.; Davidescu, M.; Roberti, R.; Corazzi, L. The energy blockers 3-bromopyruvate and lonidamine: effects on bioenergetics of brain mitochondria. J. Bioenerg. Biomembr., 2014, 46(5), 389-394.
118. Isayev, O.; Rausch, V.; Bauer, N.; Liu, L.; Fan, P.; Zhang, Y.; Gladkich, J.; Nwaeburu, C.C.; Mattern, J.; Mollenhauer, M.; Ruckert, F.; Zach, S.; Haberkorn, U.; Gross, W.; Schonsiegel, F.; Bazhin, A.V.; Herr, I. Inhibition of glucose turnover by 3-bromopyruvate counteracts pancreatic cancer stem cell features and sensitizes cells to gemcitabine. Oncotarget, 2014, 5(13), 5177-5189.
119. Matsumoto, S.; Saito, K.; Yasui, H.; Morris, H.D.; Munasinghe, J.P.; Lizak, M.; Merkle, H.; Ardenkjaer- Larsen, J.H.; Choudhuri, R.; Devasahayam, N.; Subramanian, S.; Koretsky, A.P.; Mitchell, J.B.; Krishna, M.C. EPR oxygen imaging and hyperpolarized 13C MRI of pyruvate metabolism as noninvasive biomarkers of tumor treatment response to a glycolysis inhibitor 3-bromopyruvate. Magn. Reson. Med., 2013, 69(5), 1443-1450.
120. Cardaci, S.; Rizza, S.; Filomeni, G.; Bernardini, R.; Bertocchi, F.; Mattei, M.; Paci, M.; Rotilio, G.; Ciriolo, M.R. Glutamine deprivation enhances antitumor activity of 3- bromopyruvate through the stabilization of monocarboxylate transporter-1. Cancer Res, 2012, 72(17), 4526-4536.
121. Rieber, M.; Strasberg-Rieber, M., p53 inactivation decreases dependence on estrogen/ERK signalling for proliferation but promotes EMT and susceptility to 3- bromopyruvate in ERalpha+ breast cancer MCF-7 cells. Biochem. Pharmacol., 2014, 88(2), 169-177.